实用医学杂志 ›› 2021, Vol. 37 ›› Issue (8): 1088-1092.doi: 10.3969/j.issn.1006⁃5725.2021.08.026

• 综述 • 上一篇    下一篇

坏死性凋亡机制及在结直肠肿瘤中的研究进展

胡建生, 王雯,刘海旺, 张欣颖, 孙林梅
  

  1. 1 西安市中医医院肛肠科(西安710016);2 西安交通大学护理系(西安710061);3 西安市第九医院普外科(西安710054)
  • 出版日期:2021-04-25 发布日期:2021-04-25
  • 通讯作者: 孙林梅 E⁃mail:sunlinmei@126.com
  • 基金资助:
    西安市卫健委资助项目(项目编号:J20170201)

Molecular regulation mechanism of cell necroptosis and its application in colorectal cancer

HU Jiansh⁃ eng,WANG Wen,LIU Haiwang,ZHANG Xinying,SUN Linmei.   

  1. Department of Proctology,Xi′an Hospital of Traditional Chinese Medicine,Xi′an 710016,China
  • Online:2021-04-25 Published:2021-04-25
  • Contact: SUN Linmei E⁃mail:sunlinmei@126.com

摘要:

结直肠肿瘤是常见的消化道恶性肿瘤之一,随着诊疗手段的进展其病死率有所下降,但预后仍很差。目前化疗药物治疗结直肠肿瘤主要是通过诱导细胞的死亡来抑制肿瘤的生长,然而,细胞死亡抵抗是胃肠道肿瘤治疗不成功和疾病复发的主要原因,大多数肿瘤细胞由于凋亡机制的失调而具有耐药性。新的细胞死亡方式如坏死性凋亡给结直肠肿瘤治疗带来希望,坏死性凋亡是一种Caspase非依赖 性细胞死亡方式,通常表现为坏死的形态学特征,主要通过 RIPK1 RIPK3 调控,并且由MLKL执行完成。目前,基于坏死性凋亡的结肠直肠肿瘤靶向治疗研究正在进行,提示坏死性凋亡将为结直肠肿瘤的治疗提供新策略。本篇综述重点阐述坏死性凋亡,并讨论坏死性凋亡在结直肠肿瘤发展和治疗中的作用机制。

关键词:

Abstract:

Colorectal cancer is one of the most common gastrointestinal malignancies. With the develop⁃ ment of diagnosis and treatment,the mortality has decreased,but the prognosis is still poor. At present,chemo⁃ therapy drugs used to treat colorectal cancer generally inhibit tumor growth by inducing cell death However,cell death resistance is the main reason for the unsuccessful treatment and recurrence of gastrointestinal tumors,and most tumor cells are drug⁃resistant due to the dysregulation of apoptotic mechanism. New cell death modes such as necroptosis may offer the possibility for colorectal cancer treatment. Necroptosis is a caspase ⁃independent cellular pattern,usually characterized by necrotic morphology,mainly regulated by RIPK 1 and RIPK 3,and performed by MLKL. Currently,researches on targeted therapy for colorectal cancer based on necroptosis are ongoing,suggest⁃ ing that necroptosis will provide a new strategy for the treatment of colorectal cancer. This review focuses on necrop⁃ tosis and discusses its mechanism of action in the development and treatment of colorectal cancer.

Key words:

colorectal cancer, necroptosis, receptor interacting serine/threonine ? protein kinase 1/3 (RIPK1/RIPK3), mixed lineage kinase domain?like protein(MLKL)